teva | Oncology | Canada

Brands. Generics.
Biosimilars.

PrTRUXIMA® is the first Rituxan® (rituximab) biosimilar and has been available to Canadians since 2019[1,2]*



Creative representation of a molecule.

Pr Truxima®
Rituximab for Injection
10 mg/mL Intravenous Infusion

Biosimilar by design. Biologic by essence.

Non-Hodgkin's Lymphoma (NHL)[2†‡]

TRUXIMA® (rituximab for injection) is indicated for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.

Chronic Lymphocytic Leukemia (CLL)[2‡]

TRUXIMA® (rituximab for injection) is indicated for the treatment of patients with previously untreated or previously treated B-cell chronic lymphocytic leukemia (B-CLL), Binet Stage B or C, in combination with fludarabine and cyclophosphamide.

TRUXIMA®: A proud offering from Teva Canada Innovation.

TRUXIMA® has been available in the EU since 2017.[3,4]*

For more information:

Please consult the Product Monograph at https://www.tevacanada.com/globalassets/canada-ph2/pdf-documents-en/specialty-pdfs/0620_truxima_pm_en.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, administration (administered as an intravenous [IV] infusion through a dedicated line, not administered as an IV push or bolus) and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling Teva Canada Innovation at 1-833-662-5644.

Pr Truxima®
Rituximab for Injection
10 mg/mL Intravenous Infusion

* Comparative clinical significance is unknown.
† Please refer to the TRUXIMA® Product Monograph to see the complete list of NHL indications.
‡ Indications have been granted on the basis of similarity between TRUXIMA® and the reference biologic drug Rituxan®.
EU: European Union.

References: 1. Data on File. First to market rituximab biosimilar. Teva Canada. May 31, 2019. **2.** TRUXIMA® Product Monograph. Teva Canada Limited. May 22, 2020. **3.** IQVIA. Summary of study results. June 27, 2019. **4.** Data on File. Letter of attestation for EU indications of TRUXIMA®. July 9, 2019.

08/2021
TRU20-ADH04E
PAAB